EV / EBITDA společnosti Starpharma
Jaká je hodnota metriky EV / EBITDA společnosti Starpharma?
Hodnota metriky EV / EBITDA společnosti Starpharma Holdings Limited je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na ASX ve srovnání se společností Starpharma
Čemu se věnuje společnost Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Firmy s metrikou ev / ebitda podobnou společnosti Starpharma
- Hodnota metriky EV / EBITDA společnosti AuMake International je N/A
- Hodnota metriky EV / EBITDA společnosti Hydoo International je N/A
- Hodnota metriky EV / EBITDA společnosti Damara Gold je N/A
- Hodnota metriky EV / EBITDA společnosti Kairos Minerals je N/A
- Hodnota metriky EV / EBITDA společnosti TVI Pacific je N/A
- Hodnota metriky EV / EBITDA společnosti Aurion Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Starpharma je N/A
- Hodnota metriky EV / EBITDA společnosti Diagnostic Medical Systems S.A je N/A
- Hodnota metriky EV / EBITDA společnosti Xelpmoc Design and Tech je N/A
- Hodnota metriky EV / EBITDA společnosti Just Plc je N/A
- Hodnota metriky EV / EBITDA společnosti M&L je N/A
- Hodnota metriky EV / EBITDA společnosti Takeaway.com NV je N/A
- Hodnota metriky EV / EBITDA společnosti Just Eat Takeaway.com N.V je N/A